Description: Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. Vicore Pharma Holding AB (publ) has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Home Page: www.vicorepharma.com
Kornhamnstorg 53
Stockholm,
111 27
Sweden
Phone:
46 3 17 88 05 60
Officers
| Name | Title |
|---|---|
| Mr. Ahmed S. Mousa J.D. | Chief Executive Officer |
| Mr. Hans Jeppsson Ph.D. | Chief Financial Officer |
| Mr. Mikael Nygård | Vice President of Operations & Corporate Strategy |
| Dr. Johan Raud Ph.D. | Chief Scientific Officer |
| Ms. Nina Carlen | Chief Administrative Officer |
| Ms. Megan Richards | VP of Investor Relations, Communications & Portfolio Strategy |
| Ms. Jessica Shull | Head of Digital Therapeutics & Director of Digital Innovation |
| Ms. Asa Magnusson | Chief Engagement & Commercial Officer |
| Prof. Bertil Lindmark M.D., Ph.D. | Chief Medical Officer |
| Mr. Jimmie Hofman | Vice President of Business Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3964 |
| Price-to-Sales TTM: | 1.4999 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |